Span America Medical Systems (SPAN) 10-K 23 Dec 14 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Sep. 27, 2014	Dec. 18, 2014	Mar. 29, 2014
Entity Registrant Name	SPAN AMERICA MEDICAL SYSTEMS INC
Entity Central Index Key	718924
Current Fiscal Year End Date	-18
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		2,962,007
Entity Public Float			$55,768,001
Document Type	10-K
Document Period End Date	27-Sep-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
	Sep. 27, 2014		Sep. 28, 2013		Sep. 29, 2012
Net sales	$55,857,375		$73,833,549		$76,146,423
Cost of goods sold	37,067,737		50,269,657		52,624,293
Gross profit	18,789,638		23,563,892		23,522,130
Selling and marketing expenses	10,088,400		10,722,770		10,446,961
Research and development expenses	1,071,583		1,224,174		1,100,420
General and administrative expenses	4,019,075		4,322,509		4,464,684
	15,179,058		16,269,453		16,012,065
Operating income	3,610,580		7,294,439		7,510,065
Non-operating income (expense):
Other	30,826		6,174		-23,231
Interest expense	-12,639		-15,196		-20,861
Net non-operating income (expense)	18,187		-9,022		-44,092
Income before income taxes	3,628,767		7,285,417		7,465,973
Provision for income taxes - Note 14	1,038,000		2,218,000		2,251,000
Net income	2,590,767		5,067,417		5,214,973
Other comprehensive (loss) income, after tax:
Foreign currency translation (loss) gain	-794,177		-497,647		284,396
Comprehensive income	$1,796,590		$4,569,770		$5,499,369
Net income per share:
Basic (in dollars per share)	$0.88		$1.72		$1.80
Diluted (in dollars per share)	$0.87		$1.69		$1.77
Special dividend (in dollars per share)	$0.57	[1]	$1.51	[1],[2]	$0.47	[1]
Denominator for diluted earnings per share:
Basic (in shares)	2,948,992		2,939,684		2,892,956
Diluted (in shares)	2,993,333		2,994,239		2,946,603
[1]	Dividends per share for fiscal year 2013 include a special dividend of $1.00 per share paid on December 4, 2012.
[2]	Dividends per share for fiscal year 2013 include a special dividend paid on December 4, 2012.

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Income (Parentheticals) (USD $)	12 Months Ended
	Sep. 27, 2014		Sep. 28, 2013		Sep. 29, 2012
Special dividend (in dollars per share)	$0.57	[1]	$1.51	[1],[2]	$0.47	[1]
Special Dividend [Member]
Special dividend (in dollars per share)			$1
[1]	Dividends per share for fiscal year 2013 include a special dividend of $1.00 per share paid on December 4, 2012.
[2]	Dividends per share for fiscal year 2013 include a special dividend paid on December 4, 2012.

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 27, 2014	Sep. 28, 2013
Current assets:
Cash and cash equivalents	$6,865,931	$5,424,521
Accounts receivable, net of allowances of $302,000 (2014) and $263,000 (2013)	5,851,822	7,787,837
Inventories - Note 4	7,395,955	6,445,950
Deferred income taxes - Note 14	271,828	348,950
Prepaid expenses	760,967	698,003
Total current assets	21,146,503	20,705,261
Property and equipment, net - Note 5	4,888,096	5,136,535
Goodwill	4,291,843	4,487,546
Intangibles, net - Note 7	2,860,260	3,430,349
Other assets - Note 8	2,660,132	2,616,937
	35,846,834	36,376,628
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable	2,477,198	2,658,125
Accrued and sundry liabilities - Note 9	2,051,662	2,875,600
Total current liabilities	4,528,860	5,533,725
Deferred income taxes - Note 14	160,685	194,883
Deferred compensation - Note 12	457,457	534,239
Total long-term liabilities	618,142	729,122
Total liabilities	5,147,002	6,262,847
Commitments and contingencies - Notes 20 and 21
Shareholders' equity - Note 13
Common stock, no par value, 20,000,000 shares authorized; issued and outstanding shares 2,962,007 (2014) and 2,927,416 (2013)	3,064,658	2,626,526
Additional paid-in capital	906,834	872,494
Retained earnings	27,735,768	26,828,012
Accumulated other comprehensive loss	-1,007,428	-213,251
Total shareholders' equity	30,699,832	30,113,781
	$35,846,834	$36,376,628

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Sep. 27, 2014	Sep. 28, 2013
Accounts receivable, allowances	$302,000	$263,000
Common stock, par value (in dollars per share)	$0	$0
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, shares issued (in shares)	2,962,007	2,927,416
Common stock, shares outstanding (in shares)	2,962,007	2,927,416

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
OPERATING ACTIVITIES:
Net income	$2,590,767	$5,067,417	$5,214,973
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	864,356	775,767	756,656
Amortization	424,169	509,247	452,670
Provision for losses on accounts receivable	128,925	91,623	32,008
Provision (Benefit) for deferred income taxes	50,703	166,000	-66,000
Gain on sale and disposal of property and equipment	-73	-916
Increase in cash value of life insurance	-174,943	-184,786	-194,806
Deferred compensation	-76,783	-20,048	-54,705
Stock compensation expense	26,637	34,242	72,264
Changes in operating assets and liabilities:
Accounts receivable	1,692,566	295,550	-69,307
Inventories	-1,106,616	2,898,492	520,981
Prepaid expenses and other assets	164,708	-296,204	256,544
Accounts payable and accrued and sundry liabilities	-927,407	-1,117,533	-55,964
Net cash provided by operating activities	3,657,009	8,218,851	6,865,314
INVESTING ACTIVITIES:
Acquisition of M.C. Healthcare			-8,251,831
Proceeds from sale of securities available for sale			4,000,000
Purchases of property and equipment	-670,845	-557,863	-684,327
Proceeds from sale of property and equipment	914	7,850
Payments for other assets	-80,593	-110,586	-107,528
Net cash used for investing activities	-750,524	-660,599	-5,043,686
FINANCING ACTIVITIES:
Dividends paid	-1,683,011	-4,439,382	-1,358,425
Proceeds from long-term debt			9,300,000
Repayment of long-term debt			-9,300,000
Purchase and retirement of common stock		-450,000
Proceeds from exercise of options for common stock	273,397	152,647	68,946
Net cash used for financing activities	-1,409,614	-4,736,735	-1,289,479
Effect of exchange rates on cash	-55,461	-62,298	8,747
Increase in cash and cash equivalents	1,441,410	2,759,219	540,896
Cash and cash equivalents at beginning of year	5,424,521	2,665,302	2,124,406
Cash and cash equivalents at end of year	$6,865,931	$5,424,521	$2,665,302

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (USD $)	Total	Accumulated Other Comprehensive Income (Loss) [Member]	Additional Paid-in Capital [Member]	Common Stock [Member]	Retained Earnings [Member]
Balance at Oct. 01, 2011	$24,221,123		$765,988	$1,111,706	$22,343,429
Balance (in shares) at Oct. 01, 2011				2,794,509
Net income	5,214,973				5,214,973
Foreign currency translation gain (loss)	284,396	284,396
Common stock issued for acquisition of M.C. Healthcare Products Inc. (in shares)				100,000
Common stock issued for acquisition of M.C. Healthcare Products Inc.	1,441,000			1,441,000
Common stock issued to Directors (in shares)				8,500
Common stock issued to Directors	130,390			130,390
Common stock issued on exercise of stock options (in shares)	15,741			16,241
Common stock issued on exercise of stock options	74,263			74,263
Stock option compensation expense	72,264		72,264
Cash dividends paid or declared ($.47 per share)	-1,358,425				-1,358,425
Balance at Sep. 29, 2012	30,079,984	284,396	838,252	2,757,359	26,199,977
Balance (in shares) at Sep. 29, 2012				2,919,250
Net income	5,067,417				5,067,417
Foreign currency translation gain (loss)	-497,647	-497,647
Common stock issued to Directors (in shares)				8,500
Common stock issued to Directors	164,050			164,050
Common stock issued on exercise of stock options (in shares)	24,416			24,666
Common stock issued on exercise of stock options	155,117			155,117
Stock option compensation expense	34,242		34,242
Cash dividends paid or declared ($.47 per share)	-4,439,382				-4,439,382
Stock repurchase (in shares)				-25,000
Stock repurchase	-450,000			-450,000
Balance at Sep. 28, 2013	30,113,781	-213,251	872,494	2,626,526	26,828,012
Balance (in shares) at Sep. 28, 2013	2,927,416			2,927,416
Net income	2,590,767				2,590,767
Foreign currency translation gain (loss)	-794,177	-794,177
Common stock issued to Directors (in shares)				8,500
Common stock issued to Directors	164,735			164,735
Common stock issued on exercise of stock options (in shares)	26,091			26,091
Common stock issued on exercise of stock options	273,397			273,397
Stock option compensation expense	26,637		26,637
Cash dividends paid or declared ($.47 per share)	-1,683,011				-1,683,011
Tax benefits for stock options exercised	7,703		7,703
Balance at Sep. 27, 2014	$30,699,832	($1,007,428)	$906,834	$3,064,658	$27,735,768
Balance (in shares) at Sep. 27, 2014	2,962,007			2,962,007

Consolidated_Statements_of_Cha1

Consolidated Statements of Changes in Stockholders' Equity (Parentheticals) (USD $)	12 Months Ended
	Sep. 27, 2014		Sep. 28, 2013		Sep. 29, 2012
Special dividend (in dollars per share)	$0.57	[1]	$1.51	[1],[2]	$0.47	[1]
Special Dividend [Member]
Special dividend (in dollars per share)			$1
[1]	Dividends per share for fiscal year 2013 include a special dividend of $1.00 per share paid on December 4, 2012.
[2]	Dividends per share for fiscal year 2013 include a special dividend paid on December 4, 2012.

Note_1_Significant_Accounting_

Note 1 - Significant Accounting Policies	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1	SIGNIFICANT ACCOUNTING POLICIES
	Description of Business
	Span-America Medical Systems, Inc. (the “Company,” “we,” or “Span-America”), located in Greenville, SC, manufactures and distributes therapeutic support surfaces, mattress overlays, patient positioners, seating cushions, skin care products and fall prevention products for the medical market and pillows, mattress pads and various foam products for the custom products market throughout the United States and Canada. Our wholly-owned subsidiary, Span Medical Products Canada Inc. (“Span-Canada”), located in Beamsville, Ontario, Canada, manufactures and sells hospital bed frames and related case goods, tables and seating products. We are operating Span-Canada under the registered business name M.C. Healthcare Products (“M.C. Healthcare”).
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and Span-Canada, its wholly-owned subsidiary. Significant intra-entity accounts and transactions have been eliminated.
	Cash and Cash Equivalents
	We consider all highly liquid investments with a maturity when purchased of three months or less to be cash equivalents. Depending on market conditions, we may maintain a centralized cash management program whereby our excess cash balances are invested in commercial paper and are considered cash equivalents. Cash balances in our accounts usually exceed federally insured limits.
	Accounts Receivable
	We provide credit in the normal course of business and perform ongoing credit evaluations on certain of our customers, but we generally do not require collateral to support these receivables. We also establish an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Account balances are charged against the allowance after all collection efforts have been exhausted and the potential for recovery is considered remote.
	Inventories
	Our inventories are valued at the lower of cost (first-in, first-out method) or market.
	Property and Equipment
	Property and equipment is stated at cost. Maintenance, repairs and minor replacements that do not improve or extend the useful lives of assets are expensed when incurred. Depreciation is computed using the straight-line method. Estimated useful lives for buildings and land improvements range from 15 to 35 years. The estimated useful lives of all other property and equipment range from 3 to 15 years. For income tax purposes, substantially all depreciation is computed using accelerated methods.
	Goodwill and Intangibles
	Intangible assets are amortized using the straight-line method. Costs of patents are amortized over periods ranging from 10 to 17 years, and trademarks are amortized over periods of 5 or 10 years. Trade names, non-competition agreements and customer relationships associated with the asset acquisition of M.C. Healthcare are being amortized over periods of 2.0 to 11.8 years, which represent the estimated remaining useful lives of the identifiable intangible assets. Goodwill, or costs in excess of the fair value of net assets, was acquired from three separate acquisitions. See Note 2 – Acquisition of M.C. Healthcare Products Inc. Annually as of the end of our fiscal year, we review these assets for impairment. We also review long-lived assets and the related intangible assets for impairment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. See Note 6 - Goodwill and Note 7 -Intangibles.
	Foreign Currency Translation
	Span-Canada, which operates under the registered business name, “M.C. Healthcare Products,” uses the Canadian dollar as its functional currency. The assets and liabilities of Span-Canada are translated into U.S. dollars at the year-end exchange rate. Revenues and expenses are translated at weighted average exchange rates. The resulting translation adjustments are recorded as a separate component of shareholders' equity in “Accumulated Other Comprehensive Loss.”
	Revenue Recognition
	We recognize revenue when goods are shipped and title passes to the customer. There are no customer acceptance provisions, and the right to return exists only in cases of damaged product, non-compliance with customer specifications or warranty claims. Taxes collected from customers and remitted to government authorities are recorded on a net basis (excluded from revenues).
	We have applied the accounting and disclosure requirements of Securities and Exchange Commission Staff Accounting Bulletin (“SAB”) No. 104.
	Advertising Costs
	Advertising costs are expensed as incurred.
	Shipping and Handling Costs
	Shipping and handling costs that are not reimbursed by customers are charged to selling and marketing expenses and were approximately $2,123,000 in fiscal 2014, $2,233,000 in fiscal 2013, and $2,238,000 in fiscal 2012.
	Customer
	Rebates
	We offer rebates to certain of our distributors based on predetermined sales targets. These rebates vary by the type of product sold and by distributor and are based on a percentage of the applicable sales target. The rebate expense is charged as a reduction of gross sales. Rebate expense and the associated liability are calculated and recorded as the rebate-related revenue is recognized.
	Earnings Per Share of Common Stock
	Earnings per share of common stock are computed based on the weighted average number of shares outstanding during each period.
	Stock-Based Compensation
	We measure and recognize compensation expense for all stock-based payments at fair value. Stock-based payments include stock option grants. We grant options to purchase common stock to some of our employees under various plans at prices equal to the market value of the stock on the dates the options were granted. New shares of stock are issued upon share option exercise. We do not have treasury stock.
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions for grants made in fiscal 2011: risk-free interest rate of 2.54%; dividend yield of 2.5%; volatility factor of the expected market price of our common stock of 43.02%; and a weighted average expected life of the options of 9.0 years. No options were granted during fiscal years 2014, 2013 or 2012.
	Fiscal Year
	Our fiscal year ends on the Saturday nearest to September 30. Fiscal years 2014, 2013 and 2012 were 52-week years. Fiscal year 2015 will be a 53-week year.
	Income Taxes
	The liability method is used in accounting for federal and state income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are projected to be in effect when the differences are expected to reverse. The Company’s practice is to recognize interest and penalties, if any, related to income tax matters as part of income tax expense.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes and the disclosure of contingent
	assets and liabilities. Although these estimates are based on our knowledge of current events and actions planned for the future, the estimates may ultimately differ from actual results.
	Recently Issued Accounting Standards
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued a final standard on revenue recognition that supersedes previously issued revenue recognition guidance. This standard provides a five-step approach to be applied to all contracts with customers and requires expanded disclosures about the nature, amount, timing and uncertainty of revenue (and the related cash flows) arising from customer contracts, significant judgments and changes in judgments used in applying the revenue model and the assets recognized from costs incurred to obtain or fulfill a contract.  For public entities, the provisions of the new standard are effective for annual reporting periods beginning after December 15, 2016, and early adoption is not permitted. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings.  We are currently assessing the impact of the new standard on the consolidated financial statements. We have not yet selected a transition method, nor have we determined the effect of the standard on our ongoing financial reporting.
	Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.
	Subsequent Events
	On November 12, 2014, the Company’s Board of Directors (the “Board”) declared a special cash dividend of $1.00 per share and a regular quarterly cash dividend of 15 cents ($0.15) per share. The special dividend is payable on January 7, 2015, to shareholders of record on December 17, 2014. The regular quarterly dividend is payable on December 11, 2014, to shareholders of record on November 25, 2014.
	In preparing these financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through the issuance of the financial statements.
	Reclassifications
	Certain prior year amounts have been reclassified to conform to the current year presentation in the accompanying consolidated financial statements. These reclassifications had no material effect on previously reported results of operations or retained earnings.

Note_2_Acquisition_of_MCHealth

Note 2 - Acquisition of M.C.Healthcare Products Inc.	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Business Combination Disclosure [Text Block]	2	ACQUISITION OF M.C. HEALTHCARE PRODUCTS INC.
	On December 9, 2011, we acquired, through a new wholly-owned subsidiary, substantially all of the assets of M.C. Healthcare Products Inc. (“Old M.C. Healthcare”) for approximately $9,800,000, including cash of approximately $7,980,000 at the time of closing and approximately $354,000 for the post-closing working capital adjustment, paid in January 2012, plus 100,000 shares of Span-America common stock valued at approximately $1,441,000. M.C. Healthcare manufactures medical bed frames and related products. We funded the acquisition through a combination of cash on hand, proceeds from the sale of securities available for sale and proceeds of approximately $6,500,000 from our revolving credit facility. No cash was acquired. The excess of the consideration transferred over the net tangible and intangible assets was reflected as goodwill of approximately $2,500,000.
	The allocation of the total consideration to the fair value of the assets acquired and liabilities assumed in U.S. dollars as of December 9, 2011 was as follows:
	Receivables		$	1,800,000
	Inventories			2,210,000
	Intangibles			3,980,000
	Other current assets			60,000
	Equipment			300,000
	Goodwill			2,530,000
	Liabilities assumed			(1,070,000	)
	Contingent consideration			(70,000	)
	Deferred tax liability			(50,000	)
			$	9,690,000
	The following table shows the net revenues and operating income that M.C. Healthcare contributed for the fiscal years ended 2014, 2013 and 2012. The information for fiscal 2012 includes the period from December 9, 2011, the date of the acquisition, through the fiscal year-end on September 29, 2012. These results are included in the Consolidated Financial Statements.
			2014			2013		2012
	Net revenues		$	9,721,000		$	11,305,000	$	10,284,000
	Operating income (loss)		$	(237,000	)	$	245,000	$	964,000
	Pro-forma information is shown below for fiscal year 2012 as if the purchase had occurred at the beginning of the fiscal year on October 2, 2011. See the Form 8-K/A filed on February 24, 2012 for additional information.
			2012
	Pro-forma net revenues		$	78,540,000
	Pro-forma net income			5,350,000
	Pro-forma net income per diluted share		$	1.81

Note_3_Fair_Value_of_Financial

Note 3 - Fair Value of Financial Instruments	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3	FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company accounts for the fair value measurements for financial assets and liabilities measured on a recurring basis as required by the Fair Value Measurements and Disclosures topic of the Financial Accounting Standards Board Accounting Standards Codification (“ASC”). This guidance establishes a framework for measuring fair value and expands disclosure about fair value measurements. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
	Following is a brief description of these three levels:
	Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
	Level 2 – Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
	Level 3 – Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
	The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level (with “3” being the lowest) of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.
	Following is a description of the valuation methodologies used for assets measured at fair value.
	Cash value of life insurance policy: Valued at the cash surrender value of the life insurance policy as of the last business day of the fiscal year, as determined by the issuer of the insurance policy, which approximates fair value.
	The method described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although we believe our valuation method is appropriate and consistent with methods used by other market participants, the use of different methodologies or assumptions to determine fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
	The following table summarizes information on the fair value measurement of the Company’s assets as of September 27, 2014 and September 28, 2013, grouped by the categories described above:
			Total		Quoted prices in active markets		Significant other observable inputs (Level 2)		Significant unobservable inputs
					(Level 1)				(Level 3)
	Cash value of life insurance policies	2014	$	2,493,664		-	$	2,493,664		-
		2013	$	2,318,721		-	$	2,318,721		-

Note_4_Inventories

Note 4 - Inventories	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Inventory Disclosure [Text Block]	4	INVENTORIES
			2014			2013
	Raw materials		$	5,476,050		$	5,054,462
	Work in process			517,652			698,786
	Finished goods			1,899,253			1,412,702
	Reserve for obsolescence			(497,000	)		(720,000	)
			$	7,395,955		$	6,445,950

Note_5_Property_and_Equipment

Note 5 - Property and Equipment	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5	PROPERTY AND EQUIPMENT
			2014		2013
	Land		$	469,718	$	469,718
	Land improvements			486,698		486,698
	Buildings			6,920,512		6,910,251
	Machinery and equipment			8,975,185		8,233,213
	Furniture and fixtures			490,479		488,346
	Construction in process			17,985		201,873
	Automobiles			11,313		11,461
				17,371,890		16,801,560
	Less accumulated depreciation			12,483,794		11,665,025
			$	4,888,096	$	5,136,535

Note_6_Goodwill

Note 6 - Goodwill	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Goodwill Disclosure [Text Block]	6	GOODWILL
	.
	As of September 27, 2014 and September 28, 2013, we had goodwill of $4,291,843 and $4,487,546, respectively. These amounts include goodwill from three reporting units, all of which are part of our medical segment.
	On December 9, 2011, we acquired, through a new wholly-owned subsidiary, substantially all of the assets of Old M.C. Healthcare. The following table is a reconciliation of the carrying amount of goodwill from the acquisition date of December 9, 2011 to September 27, 2014
	.
	Under Canadian tax law, a portion of goodwill acquired in connection with an asset acquisition may be amortized for tax purposes. We expect 75%, or approximately $2,000,000, of the goodwill associated with the M.C. Healthcare acquisition to be amortizable and deductible for tax purposes. See Note 2.
	Beginning balance at October 1, 2011		$	1,924,131
	Asset acquisition on December 9, 2011			6,529,885
	Adjustment for deferred taxes			53,149
	Adjustment to increase inventories to fair market value			(160,281	)
	Adjustment to allocate total consideration to other			(3,971,748	)
	intangibles based on valuation
	Adjustment to record contingent consideration			68,166
	Adjusted Goodwill at December 9, 2011			4,443,302
	Increase in foreign currency exchange rate			167,313
	Goodwill at September 29, 2012			4,610,615
	Decrease in foreign currency exchange rate			(123,069	)
	Goodwill at September 28, 2013			4,487,546
	Decrease in foreign currency exchange rate			(195,703	)
	Goodwill at September 27, 2014		$	4,291,843
	For the fiscal year ended September 27, 2014, we tested each of our three reporting units for goodwill impairment in accordance with ASC 350-20-35 Intangibles – Goodwill and Other. We determined that one reporting unit, M.C. Healthcare, was at risk of failing step one in the goodwill impairment test required under ASC 350. As of the test date, the fair value of the net assets of the M.C. Healthcare reporting unit exceeded its carrying value by 5%. Consequently, we did not recognize an impairment of the goodwill associated with this reporting unit in fiscal 2014. The amount of goodwill associated with the M.C. Healthcare reporting unit was $2,367,712 as of September 27, 2014.
	We calculate the estimated fair value of our reporting units by using an income approach, which includes internally developed discounted cash flow models. To determine fair value, we make assumptions about a number of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of sales, expenses, profit margins, working capital requirements, capital expenditures, tax rates and discount rates. These assumptions are based on our historical operating results for the M.C. Healthcare business, our detailed operating plan for fiscal year 2015 and our forecast of future business conditions. There is significant uncertainty about the various assumptions made in the analysis. Our estimates of cash flows may differ from actual cash flows due to, among other things, changes in our estimated sales and expense growth rates, other changes in our financial forecasting models, economic conditions in the U.S. and Canadian medical markets, Medicare reimbursement changes, government budget changes in the Canadian healthcare market and other risks referenced from time to time in our Securities and Exchange Commission filings. See Part 1, Item 1A – Risk Factors earlier in this report for more information on factors that could affect our assumptions used in the impairment analysis. These factors increase the risk of differences between projected and actual performance that could impact future estimates of the fair values of all reporting units. Significant differences between these estimates and actual cash flows could result in impairment charges in future periods.

Note_7_Intangibles

Note 7 - Intangibles	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	7	INTANGIBLES
			2014			2013
	Patents and trademarks		$	2,153,717		$	2,103,647
	Trade names			404,129			437,532
	Non-competition agreements			177,090			191,727
	Customer relationships			2,970,574			3,216,105
				5,705,510			5,949,011
	Less accumulated amortization			(2,845,250	)		(2,518,662	)
	Net intangibles		$	2,860,260		$	3,430,349
	On December 9, 2011, we acquired, through a new wholly-owned subsidiary, substantially all of the assets of Old M.C. Healthcare and acquired intangibles of approximately $3,980,000. At September 27, 2014 and September 28, 2013 we had intangibles associated with the asset acquisition of M.C. Healthcare of trade names, non-competition agreements and customer relationships (net of accumulated amortization of $1,005,865 and $741,480, respectively) of $2,545,928 and $3,103,884, respectively. Changes in the balances shown for trade names, non-competition agreements and customer relationships result solely from foreign currency fluctuations.
	In addition, we had patents and trademarks (net of accumulated amortization) of $314,332 as of September 27, 2014 and $326,465 as of September 28, 2013. We reviewed the useful lives of individual patents and trademarks and determined that the useful lives did not require any material changes. The intangibles and the patents and trademarks are primarily associated with the medical segment.
	Amortization expense for intangibles, patents and trademarks during fiscal years 2014, 2013, and 2012 was $394,169, $479,247, and $422,670, respectively. Estimated amortization expense for the next five fiscal years based on existing intangibles is as follows:
			Estimated
			Amortization
	Fiscal years		Expense
	2015			350,525
	2016			326,193
	2017			315,359
	2018			311,502
	2019			309,595

Note_8_Other_Assets

Note 8 - Other Assets	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Other Assets Disclosure [Text Block]	8	OTHER ASSETS
			2014		2013
	Cash value of life insurance policies - Note 3		$	2,493,664	$	2,318,721
	Other			166,468		298,216
			$	2,660,132	$	2,616,937

Note_9_Accrued_and_Sundry_Liab

Note 9 - Accrued and Sundry Liabilities	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	9	ACCRUED AND SUNDRY LIABILITIES
	.
			2014		2013
	Salaries and other compensation		$	987,713	$	1,258,897
	Federal and state income taxes and sales taxes			29,472		444,473
	Payroll taxes accrued and withheld			76,356		130,238
	Property taxes			165,482		186,796
	Medical insurance			321,635		210,551
	Warranty reserve - Note 10			257,860		318,824
	Customer rebates			199,600		236,000
	Other			13,544		89,821
			$	2,051,662	$	2,875,600

Note_10_Product_Warranties

Note 10 - Product Warranties	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Product Warranty Disclosure [Text Block]	10	PRODUCT WARRANTIES
	We offer warranties of various lengths to our customers, depending on the specific product sold. The warranties require us to repair or replace non-performing products during the warranty period at no cost to the customer. At the time revenue is recognized for products covered by warranties, we record a liability for estimated costs that may be incurred under our warranties. The costs are estimated based on historical experience, any specific warranty problems that have been identified and recovery of secondary warranty cost from component suppliers.  The amounts shown below are presented net of any expected cost recovery from suppliers. Although historical warranty costs have been within our expectations, there can be no assurance that future warranty costs will not exceed historical amounts. We regularly evaluate the adequacy of the warranty liability and adjust the balance as necessary.
	Changes in our product warranty liability for the years ended September 27, 2014 and September 28, 2013 are as follows:
			2014			2013
	Accrued liability at beginning of year		$	318,824		$	378,643
	Increase in reserve			154,479			111,872
	Expenses			(215,443	)		(171,691	)
	Accrued liability at end of year		$	257,860		$	318,824

Note_11_Revolving_Credit_Facil

Note 11 - Revolving Credit Facility	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Debt Disclosure [Text Block]	11	REVOLVING CREDIT FACILITY
	We have a revolving credit facility from a bank. The maximum principal amount we can borrow at any one time under the loan agreement is $10,000,000. The maturity date is April 30, 2015. The credit agreement is unsecured and accrues interest at a variable rate equal to 30-day LIBOR plus a margin ranging from 85 to 165 basis points, depending on our leverage ratio (as defined in the credit agreement). The interest rate, including the margin of 85 basis points, was 1.0635% in December 2012, the last time we borrowed under the credit agreement. Interest-only payments are required monthly. There is a 25-basis-point annual fee, payable quarterly, on any unused availability above $5,000,000. The credit agreement is unsecured; however, we have pledged to grant the bank a security interest in our accounts, instruments, and chattel paper upon its request in the event of a default as defined in the credit agreement. Our obligations under the credit agreement are guaranteed by Span-Canada.
	52
	The credit facility includes financial covenants relating to tangible net worth and leverage ratios, and restricts dividends and stock repurchases during any fiscal year to an aggregate amount of no more than 50% of the sum of (i) our income from continuing operations for that fiscal year plus (ii) the absolute value of our aggregate after-tax, non-cash and extraordinary losses for that fiscal year, if any. As an exception to the restriction noted above, we may pay a regular quarterly dividend in an amount no greater than the previous quarter’s regular dividend so long as we remain in compliance with the financial covenants after giving effect to the payment of the dividend. Also, there is no restriction on Span-Canada’s ability to pay dividends or make distributions to the parent company. Violation of loan covenants could result in the acceleration of the term of the credit agreement. The lending bank waived any event of default in connection with (1) our regular quarterly dividend payments of $1.7 million during fiscal year 2014, which represented 65% of our net income for the fiscal year and (2) the special dividend of $1.00 per share declared in November 2014 and payable on January 7, 2015.
	We incurred approximately $13,000, $15,000 and $21,000 of interest expense in 2014, 2013 and 2012, respectively. No amounts were outstanding under the credit facility at September 27, 2014 or September 28, 2013.

Note_12_Deferred_Compensation

Note 12 - Deferred Compensation	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Compensation Related Costs, General [Text Block]	12	DEFERRED COMPENSATION
	We are obligated to make fixed payments of approximately $114,000 per year to our founder and former chief executive officer and his ex-wife pursuant to a retirement agreement. The payments will be made for the longer of the executive’s remaining life or his ex-wife’s remaining life, if she survives him. We have fully accrued the present value of the expected payments due over the combined life expectancy of the executive and his ex-wife. We recognized expenses of approximately $37,000 in 2014, $94,000 in 2013, and $59,000 in 2012, related to this agreement. Our expenses of $94,000 in fiscal 2013 included a one-time charge of $40,000 incurred as a result of reducing the discount rate used in measuring the present value of our deferred compensation obligation from the 8% rate used in fiscal 2012 to 6% for fiscal 2013 and 2014.

Note_13_Equity_Compensation

Note 13 - Equity Compensation	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	13	EQUITY COMPENSATION
	In January 2007, the Board adopted the 2007 Equity Incentive Plan (“2007 Plan”), which was approved by our shareholders in February 2007. The 2007 Plan authorizes the Board to grant stock-based compensation awards to our officers, directors and key employees for up to 250,000 shares of Company common stock. Awards may be in the form of restricted stock, non-restricted stock, restricted stock units, options or stock appreciation rights (SARs). Total awards under the 2007 Plan may not exceed 250,000 shares, of which no more than 75,000 shares may be in the form of restricted stock, non-restricted stock or restricted stock units. The per share exercise prices of options or SARs granted under the 2007 Plan must be no less than the fair market value of a share on the grant date. The terms and conditions of each award may be set by the Board or a committee of the Board. The 2007 Plan will expire on December 31, 2016 unless terminated earlier in accordance with the 2007 Plan.
	53
	In March 1997, the Board adopted the 1997 Stock Option Plan (“1997 Plan”). The 1997 Plan authorized the Board to grant options to our key officers and employees for up to 200,000 shares of our common stock. Options granted under the 1997 Plan were generally granted at the fair market value on the date of grant. These options become exercisable and vest at the greater of 1,000 shares per year or 20% of the grant. Options expire 10 years from the date of grant for continuing employees, or three months after termination of employment for employees who leave the Company. The 1997 Plan expired by its terms on October 20, 2007. The expiration of the 1997 Plan does not affect options outstanding under the 1997 Plan, but no further options can be granted under the 1997 Plan.
	Shown below is a summary of activity under the Company’s two stock option plans.
							Outstanding								Exercisable
											Weighted								Weighted
											Average								Average
			Shares				Number of				Ex. Price				Number of				Ex. Price
			Available				Shares				Per Share				Shares				Per Share
	Balance at 10/1/11			190,500				159,562			$	9.84				130,962			$	8.74
	Fiscal Year 2012
	Granted
	Exercised							(15,741	)
	Forfeited
	Balance at 9/29/12			190,500				143,821				10.44				123,621				9.71
	Fiscal Year 2013
	Granted
	Exercised							(24,416	)
	Forfeited
	Balance at 9/28/13			190,500				119,405				11.3				107,605				10.9
	Fiscal Year 2014
	Granted
	Exercised							(26,091	)
	Forfeited
	Expired Unexercised							(322	)
	Balance at 9/27/14			190,500				92,992			$	11.53				89,592			$	11.4
	54
	Shown below is a summary of stock options outstanding and exercisable at fiscal year-end 2014.
					Outstanding												Exercisable
													Weighted
									Weighted				Average								Weighted
									Average				Remaining								Average
	Ranges of Exercise				Number of				Ex. Price				Contract				Number of				Ex. Price
	Prices				Shares				Per Share				Life (yrs)				Shares				Per Share
	$ 9.18	-	$9.67			56,992			$	9.4				2.1				56,992			$	9.4
	14.90	-	14.9			36,000				14.9				6.1				32,600				14.9
	$ 9.18	-	$14.90			92,992			$	11.53				3.6				89,592			$	11.4
	The total compensation cost related to non-vested awards not yet recognized at September 27, 2014 was $26,637
	.
	The Board adopted a stock purchase incentive plan in February 2000. The 2000 Restricted Stock Plan was created to encourage our management employees to purchase and hold Span-America common stock. Plan benefits are paid in shares of Company common stock. No benefits were earned or accrued under the plan in fiscal years 2014 or 2013. There was no vested balance of stock to be issued at September 27, 2014. Benefits earned and accrued under the plan were $2,470 in 2012. The plan expired by its terms in February 2010.

Note_14_Income_Taxes

Note 14 - Income Taxes	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Income Tax Disclosure [Text Block]	14	INCOME TAXES
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax liabilities and assets as of September 27, 2014 and September 28, 2013 are as follows:
			2014			2013
	Deferred tax liabilities:
	Depreciation		$	(275,000	)	$	(341,000	)
	Amortization			(52,000	)		(52,000	)
	Total deferred tax liabilities			(327,000	)		(393,000	)
	Deferred tax assets:
	Deferred compensation			160,000			187,000
	Accrued expenses			217,000			246,000
	Inventory			52,000			97,000
	Other			9,000			17,000
	Total deferred tax assets			438,000			547,000
	Net deferred tax assets		$	111,000		$	154,000
	We made cash income tax payments, net of refunds, of approximately $1,904,000, $2,073,000, and $1,700,000, in fiscal years 2014, 2013, and 2012, respectively.
	Federal, state and foreign income tax provisions consist of the following:
			2014			2013			2012
	Current:
	Federal		$	1,125,000		$	2,002,000		$	2,037,000
	State			20,000			34,000			46,000
	Foreign			(150,000	)		16,000			234,000
				995,000			2,052,000			2,317,000
	Deferred:
	Federal			(11,000	)		159,000			(43,000	)
	State			1,000			3,000			(4,000	)
	Foreign			53,000			4,000			(19,000	)
				43,000			166,000			(66,000	)
	Income tax expense		$	1,038,000		$	2,218,000		$	2,251,000
	Income tax expense differs from the amounts computed by applying the statutory U.S. federal tax rate to income before income taxes as follows:
			2014			2013			2012
	Computed tax at the U.S. statutory rate		$	1,234,000		$	2,477,000		$	2,538,000
	Increases (decreases):
	State income taxes, net of federal tax benefit			13,000			25,000			28,000
	Differences between U.S. and foreign tax rates			(27,000	)		(65,000	)		(107,000	)
	Officer's life insurance			(57,000	)		(60,000	)		(62,000	)
	Domestic production deduction			(116,000	)		(198,000	)		(200,000	)
	Other, net			(9,000	)		39,000			54,000
	Income tax expense		$	1,038,000		$	2,218,000		$	2,251,000
	We have adopted the provisions under ASC Topic 740, “Income Taxes” (“ASC 740”) which require that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon settlement. We recognize accrued interest and penalties related to uncertain tax positions as a component of income tax expense in our financial statements. We are not aware of any uncertain tax positions as of September 27, 2014 and September 28, 2013. In the normal course of business, we are subject to examination by taxing authorities. We do not expect to be subject to U.S. federal or state and local income tax examinations by tax authorities in filing jurisdictions for the years before tax year 2010 and Canadian tax examinations before the tax year 2011.
	Span-America files income tax returns in the U.S. and various state and local jurisdictions. Span-Canada files separate income tax returns in Canada on an annual basis.  The resulting foreign income taxes and any applicable U.S. or foreign tax implications of intercompany transactions will be accounted for within the consolidated financial reporting of income taxes, per the requirements of ASC Topic 740.
	A provision has not been made for U.S. or additional foreign taxes on $850,000 of undistributed earnings of our foreign subsidiary. Those earnings have been and will continue to be reinvested. These earnings could become subject to additional tax if they were remitted as dividends, if foreign earnings were loaned to Span-America or a U.S. affiliate, or if we sold our stock in the Span-Canada subsidiary. It is not practicable to estimate the amount of additional tax that might be payable on the foreign earnings.

Note_15_Earnings_Per_Share_of_

Note 15 - Earnings Per Share of Common Stock	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Earnings Per Share [Text Block]	15	EARNINGS PER SHARE OF COMMON STOCK
	The following table sets forth the computation of basic and diluted earnings per share of common stock.
			2014		2013		2012
	Numerator for basic and diluted
	earnings per share:
	Net income		$	2,590,767	$	5,067,417	$	5,214,973
	Denominator:
	Denominator for basic earnings per share:
	Weighted average shares			2,948,992		2,939,684		2,892,956
	Effect of dilutive securities:
	Employee stock options			44,341		54,555		53,647
	Denominator for diluted earnings per share:
	Adjusted weighted average shares			2,993,333		2,994,239		2,946,603
	and assumed conversions
	Net income per share:
	Basic		$	0.88	$	1.72	$	1.8
	Diluted		$	0.87	$	1.69	$	1.77

Note_16_Employee_Benefits_and_

Note 16 - Employee Benefits and Incentive Plans	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	16	EMPLOYEE BENEFITS AND INCENTIVE PLANS
	We have a 401(k) plan available to employees meeting eligibility requirements. We match a percentage of employee contributions, with certain limitations. Our 401(k) matching contributions amounted to approximately $184,000, $202,000, and $190,000, for the 2014, 2013, and 2012 fiscal years, respectively.

Note_17_RelatedParty_Transacti

Note 17 - Related-Party Transactions	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	17	RELATED-PARTY TRANSACTIONS
	In August 2013, we repurchased 25,000 shares of company stock at $18.00 per share for a total of $450,000 from the former owner of M.C. Healthcare. The repurchased shares were originally issued as part of the purchase price of our acquisition of M.C. Healthcare in December 2011. They were repurchased under an existing repurchase program authorized by the Board. Our lending bank waived any event of default in connection with the repurchase of these 25,000 shares.

Note_18_Major_Customers

Note 18 - Major Customers	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	1	MAJOR CUSTOMERS
	8
	.
	The largest of our medical customers are distributors who sell our products to acute care hospitals and long-term care facilities throughout the United States and Canada. One of our medical customers acquired another of our medical customers during fiscal 2013. If the customers had been under common ownership since 2012, sales to that customer would have been 13% of total net sales in fiscal 2013 and 11% in fiscal 2012. Sales to that customer were 17% of total net sales in fiscal 2014.
	We have a business relationship with another customer to distribute certain of our consumer products. Sales to this customer amounted to 16% of total net sales in fiscal 2014, 32% in fiscal 2013 and 34% in fiscal 2012.
	See Note 19 for further information about sales to major customers.

Note_19_Operations_and_Industr

Note 19 - Operations and Industry Segments and Geographic Areas	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1	OPERATIONS AND INDUSTRY SEGMENTS AND GEOGRAPHIC AREAS
	9
	.
	For management and reporting purposes, we divide our business into two segments: medical and custom products. This industry segment information corresponds to the markets in the United States and Canada for which we manufacture and distribute our various products. The following table summarizes certain information on industry segments:
			2014			2013			2012
	Net sales:
	Medical		$	42,334,896		$	47,531,676		$	46,452,008
	Custom products			13,522,479			26,301,873			29,694,415
			$	55,857,375		$	73,833,549		$	76,146,423
	Operating profit:
	Medical		$	3,966,605		$	5,446,274		$	5,349,910
	Custom products			257,997			2,509,105			2,797,465
				4,224,602			7,955,379			8,147,375
	Corporate expense			(614,022	)		(660,940	)		(637,310	)
	Other income (expense)			18,187			(9,022	)		(44,092	)
	Income before income taxes		$	3,628,767		$	7,285,417		$	7,465,973
	Identifiable assets:
	Medical		$	22,221,526		$	22,512,205		$	23,814,524
	Custom products			3,991,467			5,769,403			9,030,782
	Corporate			9,633,841			8,095,020			4,802,460
			$	35,846,834		$	36,376,628		$	37,647,766
			2014			2013			2012
	Depreciation and amortization expenses:
	Operating:
	Medical		$	1,069,882		$	987,851		$	872,909
	Custom products			218,234			296,754			336,114
	Corporate			409			409			303
			$	1,288,525		$	1,285,014		$	1,209,326
	Capital expenditures:
	Medical		$	595,002		$	476,928		$	477,658
	Custom products			75,843			80,935			206,669
			$	670,845		$	557,863		$	684,327
	Geographic Areas:
	Net sales:
	United States		$	49,804,659		$	66,222,867		$	67,981,932
	Canada			5,922,543			7,506,498			7,920,424
	Other			130,173			104,184			244,067
			$	55,857,375		$	73,833,549		$	76,146,423
	Property and Equipment, net:
	United States		$	4,181,361		$	4,515,702		$	5,043,260
	Canada			706,735			620,833			347,415
			$	4,888,096		$	5,136,535		$	5,390,675
	Goodwill:
	United States		$	1,924,131		$	1,924,131		$	1,924,131
	Canada			2,367,712			2,563,415			2,686,484
			$	4,291,843		$	4,487,546		$	4,610,615
	Intangibles, net:
	United States		$	303,456		$	326,465		$	313,925
	Canada			2,556,804			3,103,884			3,676,962
			$	2,860,260		$	3,430,349		$	3,990,887
	Total sales by industry segment include sales to unaffiliated customers as reported in our statements of income. In calculating operating profit, non-allocable general corporate expenses, interest expense, other income and income taxes are not included, but certain corporate operating expenses incurred for the benefit of all segments are included on an allocated basis.
	Identifiable assets are those assets that are used in the operations of each segment on an allocated basis. Amounts shown for corporate assets consist primarily of cash and cash surrender value of life insurance.
	Included in the consolidated balance sheet at September 27, 2014 and September 28, 2013, are the net assets of Span Canada’s operations located in a single facility in Canada, which total approximately $10,000,000 and $11,000,000, respectively.
	We have several customers whose sales represent significant portions of sales in their respective business segments. One of our medical customers acquired another of our medical customers during fiscal 2013. If the customers had been under common ownership since 2012, sales to that customer would have been 21% of net medical sales in fiscal 2013 and 17% in fiscal 2012. Sales to this customer were 22% of net medical sales in fiscal 2014.
	Sales to another medical customer accounted for 11% of net medical sales in fiscal 2014 and 9% in fiscal years 2013 and 2012.
	In the custom products segment, sales to one customer accounted for 66% of net custom products sales in fiscal 2014 and 88% in fiscal years 2013 and 2012.

Note_20_Operating_Leases

Note 20 - Operating Leases	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	20	OPERATING LEASES
	.
	We lease truck equipment in South Carolina. In addition, we lease a 15,000 square foot distribution facility in Utah for $7,500 a month. The Utah facility lease is cancellable by either party with 60 days’ notice. Both leases require us to pay certain insurance and maintenance costs.
	Rental expense for all operating leases was $375,000 in fiscal 2014, $424,000 in fiscal 2013, and $414,000 in fiscal 2012.
	In connection with our acquisition of M.C. Healthcare on December 9, 2011, we signed a five-year commitment to lease Old M.C. Healthcare’s 50,000 square foot manufacturing and showroom facility in Beamsville, Ontario
	at CDN $265,000 per year. The lease includes a one-time option, exercisable in the last year of the initial lease term, to buy the property or renew the lease for an additional five years.

Note_21_Commitments_and_Contin

Note 21 - Commitments and Contingencies	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	2	COMMITMENTS AND CONTINGENCIES
	1
	.
	We are committed to minimum purchases of $700,000 of Selan® skin care products per calendar year for each calendar year through 2015. For the fiscal years ended 2014, 2013 and 2012, purchases under this commitment were $898,000, $1,047,000, and $898,000, respectively.
	From time to time we are defendants in legal actions involving claims arising in the normal course of business. We believe that, as a result of legal defenses and insurance arrangements with parties we believe to be financially capable, none of these actions, if determined adversely, should have a material adverse effect on our operations or financial condition.

Note_22_Quarterly_Financial_Da

Note 22 - Quarterly Financial Data	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Quarterly Financial Information [Text Block]	2	QUARTERLY FINANCIAL DATA (Unaudited)
	2
	.
	Quarterly Financial Data (Unaudited)
	(Amounts in thousands, except per share data)
			First		Second		Third		Fourth		Year
	For Fiscal 2014
	Net sales		$	14,853	$	14,709	$	13,251	$	13,045	$	55,857
	Gross profit			4,788		5,253		4,343		4,405		18,790
	Operating income			1,005		1,341		563		702		3,611
	Net income			666		891		378		656		2,591
	Earnings per share
	Basic			0.23		0.3		0.13		0.22		0.88
	Diluted			0.22		0.3		0.13		0.22		0.87
	For Fiscal 2013
	Net sales		$	21,661	$	16,623	$	18,621	$	16,929	$	73,834
	Gross profit			6,143		5,777		6,225		5,419		23,564
	Operating income			2,077		1,813		1,814		1,590		7,294
	Net income			1,364		1,234		1,223		1,247		5,067
	Earnings per share
	Basic			0.47		0.42		0.41		0.42		1.72
	Diluted			0.46		0.41		0.41		0.42		1.69

Note_23_Schedule_VIII_Valuatio

Note 23 - Schedule VIII Valuation and Qualifying Accounts	12 Months Ended
	Sep. 27, 2014
Notes to Financial Statements
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	Schedule VIII Valuation and Qualifying Accounts
		Balance at		Charged to							Balance at
		Beginning of		Costs and		Deductions-			( c )		End of
	Description	Period		Expenses		Describe			Adjustments		Period
	Fiscal Year Ended September 27, 2014
	Deducted from asset accounts:
	Reserve for uncollectible accounts	$	263,000	$	128,925	$	89,925	(a)			$	302,000
	Reserve for obsolete inventory	$	720,000	$	95,303	$	318,303	(b)			$	497,000
	Fiscal Year Ended September 28, 2013
	Deducted from asset accounts:
	Reserve for uncollectible accounts	$	233,000	$	91,623	$	61,623	(a)			$	263,000
	Reserve for obsolete inventory	$	595,000	$	145,000	$	20,000	(b)			$	720,000
	Fiscal Year Ended September 29, 2012
	Deducted from asset accounts:
	Reserve for uncollectible accounts	$	150,000	$	32,000	$	9,000	(a)	$	60,000	$	233,000
	Reserve for obsolete inventory	$	245,000	$	127,000	$	7,000	(b)	$	230,000	$	595,000
	(a) Uncollectible accounts written off
	(b) Inventory disposed of
	(c) Adjustments related to acquisitions and translation
	All other schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are not required under the related instructions or are inapplicable, and therefore have been omitted.

Significant_Accounting_Policie

Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 27, 2014
Accounting Policies [Abstract]
Receivables, Policy [Policy Text Block]	Accounts Receivable
	We provide credit in the normal course of business and perform ongoing credit evaluations on certain of our customers, but we generally do not require collateral to support these receivables. We also establish an allowance for doubtful accounts based upon factors surrounding the credit risk of specific customers, historical trends and other information. Account balances are charged against the allowance after all collection efforts have been exhausted and the potential for recovery is considered remote.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Costs
	Shipping and handling costs that are not reimbursed by customers are charged to selling and marketing expenses and were approximately $2,105,000 in 2014, $2,233,000 in 2013, and $2,238,000 in 2012.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	We consider all highly liquid investments with a maturity when purchased of three months or less to be cash equivalents. Depending on market conditions, we may maintain a centralized cash management program whereby our excess cash balances are invested in commercial paper and are considered cash equivalents. Cash balances in our accounts usually exceed federally insured limits.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation
	We measure and recognize compensation expense for all stock-based payments at fair value. Stock-based payments include stock option grants. We grant options to purchase common stock to some of our employees under various plans at prices equal to the market value of the stock on the dates the options were granted. New shares of stock are issued upon share option exercise. We do not have treasury stock.
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions for grants made in fiscal 2011: risk-free interest rate of 2.54%; dividend yield of 2.5%; volatility factor of the expected market price of our common stock of 43.02%; and a weighted average expected life of the options of 9.0 years. No options were granted during fiscal years 2014, 2013 or 2012.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	We recognize revenue when goods are shipped and title passes to the customer. There are no customer acceptance provisions, and the right to return exists only in cases of damaged product, non-compliance with customer specifications or warranty claims. Taxes collected from customers and remitted to government authorities are recorded on a net basis (excluded from revenues).
	We have applied the accounting and disclosure requirements of Securities and Exchange Commission Staff Accounting Bulletin (“SAB”) No. 104.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events
	On November 14, 2014, the Company’s Board of Directors (the “Board”) declared a special cash dividend of $1.00 per share and a regular quarterly cash dividend of 15 cents ($0.15) per share. The special dividend is payable on January 7, 2015, to shareholders of record on December 17, 2014. The regular quarterly dividend is payable on December 11, 2014, to shareholders of record on November 25, 2014.
	In preparing these financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through the issuance of the financial statements.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation
	Span-Canada, which operates under the registered business name, “M.C. Healthcare Products,” uses the Canadian dollar as its functional currency. The assets and liabilities of Span-Canada are translated into U.S. dollars at the year-end exchange rate. Revenues and expenses are translated at weighted average exchange rates. The resulting translation adjustments are recorded as a separate component of shareholders' equity.
Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block]	Advertising Costs
	Advertising costs are expensed as incurred.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes and the disclosure of contingent
	assets and liabilities. Although these estimates are based on our knowledge of current events and actions planned for the future, the estimates may ultimately differ from actual results.
Inventory, Policy [Policy Text Block]	Inventories
	Our inventories are valued at the lower of cost (first-in, first-out method) or market.
Income Tax, Policy [Policy Text Block]	Income Taxes
	The liability method is used in accounting for federal and state income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are projected to be in effect when the differences are expected to reverse. The Company’s practice is to recognize interest and penalties, if any, related to income tax matters as part of income tax expense.
Fiscal Period, Policy [Policy Text Block]	Fiscal Year
	Our fiscal year ends on the Saturday nearest to September 30. Fiscal years 2014, 2013 and 2012 were 52-week years. Fiscal year 2015 will be a 53-week year.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and Intangibles
	Intangible assets are amortized using the straight-line method. Costs of patents are amortized over periods ranging from 10 to 17 years, and trademarks are amortized over periods of 5 or 10 years. Trade names, non-competition agreements and customer relationships associated with the asset acquisition of M.C. Healthcare are being amortized over periods of 2.0 to 11.8 years, which represent the estimated remaining useful lives of the identifiable intangible assets. Goodwill, or costs in excess of the fair value of net assets, was acquired from three separate acquisitions. See Note 2 – Acquisition of M.C. Healthcare Products Inc. Annually as of the end of our fiscal year, we review these assets for impairment. We also review long-lived assets and the related intangible assets for impairment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. See Note 6 - Goodwill and Note 7 -Intangibles.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and Span-Canada, its wholly-owned subsidiary. Significant intra-entity accounts and transactions have been eliminated.
Reclassification, Policy [Policy Text Block]	Reclassifications
	Certain prior year amounts have been reclassified to conform to the current year presentation in the accompanying consolidated financial statements. These reclassifications had no material effect on previously reported results of operations or retained earnings.
Earnings Per Share, Policy [Policy Text Block]	Earnings Per Share of Common Stock
	Earnings per share of common stock are computed based on the weighted average number of shares outstanding during each period.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Standards
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued a final standard on revenue recognition that supersedes previously issued revenue recognition guidance. This standard provides a five-step approach to be applied to all contracts with customers and requires expanded disclosures about the nature, amount, timing and uncertainty of revenue (and the related cash flows) arising from customer contracts, significant judgments and changes in judgments used in applying the revenue model and the assets recognized from costs incurred to obtain or fulfill a contract.  For public entities, the provisions of the new standard are effective for annual reporting periods beginning after December 15, 2016, and early adoption is not permitted. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings.  We are currently assessing the impact of the new standard on the consolidated financial statements. We have not yet selected a transition method, nor have we determined the effect of the standard on our ongoing financial reporting.
	Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
	Property and equipment is stated at cost. Maintenance, repairs and minor replacements that do not improve or extend the useful lives of assets are expensed when incurred. Depreciation is computed using the straight-line method. Estimated useful lives for buildings and land improvements range from 15 to 35 years. The estimated useful lives of all other property and equipment range from 3 to 15 years. For income tax purposes, substantially all depreciation is computed using accelerated methods.
Revenue Recognition, Rebates [Policy Text Block]	Customer
	Rebates
	We offer rebates to certain of our distributors based on predetermined sales targets. These rebates vary by the type of product sold and by distributor and are based on a percentage of the applicable sales target. The rebate expense is charged as a reduction of gross sales. Rebate expense and the associated liability are calculated and recorded as the rebate-related revenue is recognized.

Note_2_Acquisition_of_MCHealth1

Note 2 - Acquisition of M.C.Healthcare Products Inc. (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Receivables	$	1,800,000
	Inventories		2,210,000
	Intangibles		3,980,000
	Other current assets		60,000
	Equipment		300,000
	Goodwill		2,530,000
	Liabilities assumed		(1,070,000	)
	Contingent consideration		(70,000	)
	Deferred tax liability		(50,000	)
		$	9,690,000
Business Acquisition, Pro Forma Information [Table Text Block]		2012
	Pro-forma net revenues	$	78,540,000
	Pro-forma net income		5,350,000
	Pro-forma net income per diluted share	$	1.81
Scenario, Actual [Member]
Notes Tables
Business Acquisition, Pro Forma Information [Table Text Block]		2014			2013		2012
	Net revenues	$	9,721,000		$	11,305,000	$	10,284,000
	Operating income (loss)	$	(237,000	)	$	245,000	$	964,000

Note_3_Fair_Value_of_Financial1

Note 3 - Fair Value of Financial Instruments (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]			Total		Quoted prices in active markets		Significant other observable inputs (Level 2)		Significant unobservable inputs
					(Level 1)				(Level 3)
	Cash value of life insurance policies	2014	$	2,493,664		-	$	2,493,664		-
		2013	$	2,318,721		-	$	2,318,721		-

Note_4_Inventories_Tables

Note 4 - Inventories (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Schedule of Inventory, Current [Table Text Block]		2014			2013
	Raw materials	$	5,476,050		$	5,054,462
	Work in process		517,652			698,786
	Finished goods		1,899,253			1,412,702
	Reserve for obsolescence		(497,000	)		(720,000	)
		$	7,395,955		$	6,445,950

Note_5_Property_and_Equipment_

Note 5 - Property and Equipment (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Property, Plant and Equipment [Table Text Block]		2014		2013
	Land	$	469,718	$	469,718
	Land improvements		486,698		486,698
	Buildings		6,920,512		6,910,251
	Machinery and equipment		8,975,185		8,233,213
	Furniture and fixtures		490,479		488,346
	Construction in process		17,985		201,873
	Automobiles		11,313		11,461
			17,371,890		16,801,560
	Less accumulated depreciation		12,483,794		11,665,025
		$	4,888,096	$	5,136,535

Note_6_Goodwill_Tables

Note 6 - Goodwill (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Schedule of Goodwill [Table Text Block]	Beginning balance at October 1, 2011	$	1,924,131
	Asset acquisition on December 9, 2011		6,529,885
	Adjustment for deferred taxes		53,149
	Adjustment to increase inventories to fair market value		(160,281	)
	Adjustment to allocate total consideration to other		(3,971,748	)
	intangibles based on valuation
	Adjustment to record contingent consideration		68,166
	Adjusted Goodwill at December 9, 2011		4,443,302
	Increase in foreign currency exchange rate		167,313
	Goodwill at September 29, 2012		4,610,615
	Decrease in foreign currency exchange rate		(123,069	)
	Goodwill at September 28, 2013		4,487,546
	Decrease in foreign currency exchange rate		(195,703	)
	Goodwill at September 27, 2014	$	4,291,843

Note_7_Intangibles_Tables

Note 7 - Intangibles (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]		2014			2013
	Patents and trademarks	$	2,153,717		$	2,103,647
	Trade names		404,129			437,532
	Non-competition agreements		177,090			191,727
	Customer relationships		2,970,574			3,216,105
			5,705,510			5,949,011
	Less accumulated amortization		(2,845,250	)		(2,518,662	)
	Net intangibles	$	2,860,260		$	3,430,349
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]		Estimated
		Amortization
	Fiscal years	Expense
	2015		350,525
	2016		326,193
	2017		315,359
	2018		311,502
	2019		309,595

Note_8_Other_Assets_Tables

Note 8 - Other Assets (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Schedule of Other Assets, Noncurrent [Table Text Block]		2014		2013
	Cash value of life insurance policies - Note 3	$	2,493,664	$	2,318,721
	Other		166,468		298,216
		$	2,660,132	$	2,616,937

Note_9_Accrued_and_Sundry_Liab1

Note 9 - Accrued and Sundry Liabilities (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]		2014		2013
	Salaries and other compensation	$	987,713	$	1,258,897
	Federal and state income taxes and sales taxes		29,472		444,473
	Payroll taxes accrued and withheld		76,356		130,238
	Property taxes		165,482		186,796
	Medical insurance		321,635		210,551
	Warranty reserve - Note 10		257,860		318,824
	Customer rebates		199,600		236,000
	Other		13,544		89,821
		$	2,051,662	$	2,875,600

Note_10_Product_Warranties_Tab

Note 10 - Product Warranties (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]		2014			2013
	Accrued liability at beginning of year	$	318,824		$	378,643
	Increase in reserve		154,479			111,872
	Expenses		(215,443	)		(171,691	)
	Accrued liability at end of year	$	257,860		$	318,824

Note_13_Equity_Compensation_Ta

Note 13 - Equity Compensation (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]							Outstanding								Exercisable
											Weighted								Weighted
											Average								Average
			Shares				Number of				Ex. Price				Number of				Ex. Price
			Available				Shares				Per Share				Shares				Per Share
	Balance at 10/1/11			190,500				159,562			$	9.84				130,962			$	8.74
	Fiscal Year 2012
	Granted
	Exercised							(15,741	)
	Forfeited
	Balance at 9/29/12			190,500				143,821				10.44				123,621				9.71
	Fiscal Year 2013
	Granted
	Exercised							(24,416	)
	Forfeited
	Balance at 9/28/13			190,500				119,405				11.3				107,605				10.9
	Fiscal Year 2014
	Granted
	Exercised							(26,091	)
	Forfeited
	Expired Unexercised							(322	)
	Balance at 9/27/14			190,500				92,992			$	11.53				89,592			$	11.4
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]					Outstanding												Exercisable
													Weighted
									Weighted				Average								Weighted
									Average				Remaining								Average
	Ranges of Exercise				Number of				Ex. Price				Contract				Number of				Ex. Price
	Prices				Shares				Per Share				Life (yrs)				Shares				Per Share
	$ 9.18	-	$9.67			56,992			$	9.4				2.1				56,992			$	9.4
	14.90	-	14.9			36,000				14.9				6.1				32,600				14.9
	$ 9.18	-	$14.90			92,992			$	11.53				3.6				89,592			$	11.4

Note_14_Income_Taxes_Tables

Note 14 - Income Taxes (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]		2014			2013
	Deferred tax liabilities:
	Depreciation	$	(275,000	)	$	(341,000	)
	Amortization		(52,000	)		(52,000	)
	Total deferred tax liabilities		(327,000	)		(393,000	)
	Deferred tax assets:
	Deferred compensation		160,000			187,000
	Accrued expenses		217,000			246,000
	Inventory		52,000			97,000
	Other		9,000			17,000
	Total deferred tax assets		438,000			547,000
	Net deferred tax assets	$	111,000		$	154,000
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]		2014			2013			2012
	Current:
	Federal	$	1,125,000		$	2,002,000		$	2,037,000
	State		20,000			34,000			46,000
	Foreign		(150,000	)		16,000			234,000
			995,000			2,052,000			2,317,000
	Deferred:
	Federal		(11,000	)		159,000			(43,000	)
	State		1,000			3,000			(4,000	)
	Foreign		53,000			4,000			(19,000	)
			43,000			166,000			(66,000	)
	Income tax expense	$	1,038,000		$	2,218,000		$	2,251,000
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		2014			2013			2012
	Computed tax at the U.S. statutory rate	$	1,234,000		$	2,477,000		$	2,538,000
	Increases (decreases):
	State income taxes, net of federal tax benefit		13,000			25,000			28,000
	Differences between U.S. and foreign tax rates		(27,000	)		(65,000	)		(107,000	)
	Officer's life insurance		(57,000	)		(60,000	)		(62,000	)
	Domestic production deduction		(116,000	)		(198,000	)		(200,000	)
	Other, net		(9,000	)		39,000			54,000
	Income tax expense	$	1,038,000		$	2,218,000		$	2,251,000

Note_15_Earnings_Per_Share_of_1

Note 15 - Earnings Per Share of Common Stock (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]		2014		2013		2012
	Numerator for basic and diluted
	earnings per share:
	Net income	$	2,590,767	$	5,067,417	$	5,214,973
	Denominator:
	Denominator for basic earnings per share:
	Weighted average shares		2,948,992		2,939,684		2,892,956
	Effect of dilutive securities:
	Employee stock options		44,341		54,555		53,647
	Denominator for diluted earnings per share:
	Adjusted weighted average shares		2,993,333		2,994,239		2,946,603
	and assumed conversions
	Net income per share:
	Basic	$	0.88	$	1.72	$	1.8
	Diluted	$	0.87	$	1.69	$	1.77

Note_19_Operations_and_Industr1

Note 19 - Operations and Industry Segments and Geographic Areas (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]		2014			2013			2012
	Net sales:
	Medical	$	42,334,896		$	47,531,676		$	46,452,008
	Custom products		13,522,479			26,301,873			29,694,415
		$	55,857,375		$	73,833,549		$	76,146,423
	Operating profit:
	Medical	$	3,966,605		$	5,446,274		$	5,349,910
	Custom products		257,997			2,509,105			2,797,465
			4,224,602			7,955,379			8,147,375
	Corporate expense		(614,022	)		(660,940	)		(637,310	)
	Other income (expense)		18,187			(9,022	)		(44,092	)
	Income before income taxes	$	3,628,767		$	7,285,417		$	7,465,973
	Identifiable assets:
	Medical	$	22,221,526		$	22,512,205		$	23,814,524
	Custom products		3,991,467			5,769,403			9,030,782
	Corporate		9,633,841			8,095,020			4,802,460
		$	35,846,834		$	36,376,628		$	37,647,766
		2014			2013			2012
	Depreciation and amortization expenses:
	Operating:
	Medical	$	1,069,882		$	987,851		$	872,909
	Custom products		218,234			296,754			336,114
	Corporate		409			409			303
		$	1,288,525		$	1,285,014		$	1,209,326
	Capital expenditures:
	Medical	$	595,002		$	476,928		$	477,658
	Custom products		75,843			80,935			206,669
		$	670,845		$	557,863		$	684,327
	Geographic Areas:
	Net sales:
	United States	$	49,804,659		$	66,222,867		$	67,981,932
	Canada		5,922,543			7,506,498			7,920,424
	Other		130,173			104,184			244,067
		$	55,857,375		$	73,833,549		$	76,146,423
	Property and Equipment, net:
	United States	$	4,181,361		$	4,515,702		$	5,043,260
	Canada		706,735			620,833			347,415
		$	4,888,096		$	5,136,535		$	5,390,675
	Goodwill:
	United States	$	1,924,131		$	1,924,131		$	1,924,131
	Canada		2,367,712			2,563,415			2,686,484
		$	4,291,843		$	4,487,546		$	4,610,615
	Intangibles, net:
	United States	$	303,456		$	326,465		$	313,925
	Canada		2,556,804			3,103,884			3,676,962
		$	2,860,260		$	3,430,349		$	3,990,887

Note_22_Quarterly_Financial_Da1

Note 22 - Quarterly Financial Data (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Schedule of Quarterly Financial Information [Table Text Block]		First		Second		Third		Fourth		Year
	For Fiscal 2014
	Net sales	$	14,853	$	14,709	$	13,251	$	13,045	$	55,857
	Gross profit		4,788		5,253		4,343		4,405		18,790
	Operating income		1,005		1,341		563		702		3,611
	Net income		666		891		378		656		2,591
	Earnings per share
	Basic		0.23		0.3		0.13		0.22		0.88
	Diluted		0.22		0.3		0.13		0.22		0.87
	For Fiscal 2013
	Net sales	$	21,661	$	16,623	$	18,621	$	16,929	$	73,834
	Gross profit		6,143		5,777		6,225		5,419		23,564
	Operating income		2,077		1,813		1,814		1,590		7,294
	Net income		1,364		1,234		1,223		1,247		5,067
	Earnings per share
	Basic		0.47		0.42		0.41		0.42		1.72
	Diluted		0.46		0.41		0.41		0.42		1.69

Note_23_Schedule_VIII_Valuatio1

Note 23 - Schedule VIII Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Sep. 27, 2014
Notes Tables
Valuation and Qualifying Accounts [Table Text Block]
		Balance at		Charged to							Balance at
		Beginning of		Costs and		Deductions-			( c )		End of
	Description	Period		Expenses		Describe			Adjustments		Period
	Fiscal Year Ended September 27, 2014
	Deducted from asset accounts:
	Reserve for uncollectible accounts	$	263,000	$	128,925	$	89,925	(a)			$	302,000
	Reserve for obsolete inventory	$	720,000	$	95,303	$	318,303	(b)			$	497,000
	Fiscal Year Ended September 28, 2013
	Deducted from asset accounts:
	Reserve for uncollectible accounts	$	233,000	$	91,623	$	61,623	(a)			$	263,000
	Reserve for obsolete inventory	$	595,000	$	145,000	$	20,000	(b)			$	720,000
	Fiscal Year Ended September 29, 2012
	Deducted from asset accounts:
	Reserve for uncollectible accounts	$	150,000	$	32,000	$	9,000	(a)	$	60,000	$	233,000
	Reserve for obsolete inventory	$	245,000	$	127,000	$	7,000	(b)	$	230,000	$	595,000

Note_1_Significant_Accounting_1

Note 1 - Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended							0 Months Ended
	Sep. 27, 2014		Sep. 28, 2013		Sep. 29, 2012		Oct. 01, 2011	Nov. 14, 2014
Accounting Policies [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0		0		0
Common Stock, Dividends, Per Share, Declared	$0.57	[1]	$1.51	[1],[2]	$0.47	[1]
Shipping, Handling and Transportation Costs	$2,123,000		$2,233,000		$2,238,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							2.54%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate							2.50%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							43.02%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term							9 years
Subsequent Event [Member]
Accounting Policies [Abstract]
Common Stock, Dividends, Per Share, Declared								$0.15
Land, Buildings and Improvements [Member] | Maximum [Member]
Accounting Policies [Abstract]
Property, Plant and Equipment, Useful Life	35 years
Land, Buildings and Improvements [Member] | Minimum [Member]
Accounting Policies [Abstract]
Property, Plant and Equipment, Useful Life	15 years
Property, Plant and Equipment, Other Types [Member] | Maximum [Member]
Accounting Policies [Abstract]
Property, Plant and Equipment, Useful Life	15 years
Property, Plant and Equipment, Other Types [Member] | Minimum [Member]
Accounting Policies [Abstract]
Property, Plant and Equipment, Useful Life	3 years
Patents [Member] | Maximum [Member]
Accounting Policies [Abstract]
Finite-Lived Intangible Asset, Useful Life	17 years
Patents [Member] | Minimum [Member]
Accounting Policies [Abstract]
Finite-Lived Intangible Asset, Useful Life	10 years
Trademarks [Member] | Maximum [Member]
Accounting Policies [Abstract]
Finite-Lived Intangible Asset, Useful Life	10 years
Trademarks [Member] | Minimum [Member]
Accounting Policies [Abstract]
Finite-Lived Intangible Asset, Useful Life	5 years
M C H P Acquisition Trade Names Non Compete Agreements And Customer Relationships [Member] | Maximum [Member]
Accounting Policies [Abstract]
Finite-Lived Intangible Asset, Useful Life	11 years 292 days
M C H P Acquisition Trade Names Non Compete Agreements And Customer Relationships [Member] | Minimum [Member]
Accounting Policies [Abstract]
Finite-Lived Intangible Asset, Useful Life	2 years
Special Dividend [Member]
Accounting Policies [Abstract]
Common Stock, Dividends, Per Share, Declared			$1
Special Dividend [Member] | Subsequent Event [Member]
Accounting Policies [Abstract]
Common Stock, Dividends, Per Share, Declared								$1
[1]	Dividends per share for fiscal year 2013 include a special dividend of $1.00 per share paid on December 4, 2012.
[2]	Dividends per share for fiscal year 2013 include a special dividend paid on December 4, 2012.

Note_2_Acquisition_of_MCHealth2

Note 2 - Acquisition of M.C.Healthcare Products Inc. (Details Textual) (USD $)	0 Months Ended
	Dec. 09, 2011	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012	Oct. 01, 2011	Jan. 31, 2012
Business Combinations [Abstract]
Goodwill	$4,443,302	$4,291,843	$4,487,546	$4,610,615	$1,924,131
M.C. Healthcare Products "MCHP" [Member]
Business Combinations [Abstract]
Cash Acquired from Acquisition	0
Business Combination, Consideration Transferred	9,800,000
Payments to Acquire Businesses, Gross	7,980,000
Business Acquisition Payment For Post Closing Working Capital Adjustment						354,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	100,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	1,441,000
Proceeds from Lines of Credit	6,500,000
Goodwill	$2,530,000	$2,367,712

Note_2_Purchase_Price_Allocati

Note 2 - Purchase Price Allocation (Details) (USD $)	Dec. 09, 2011
Goodwill	$4,443,302
M.C. Healthcare Products "MCHP" [Member]
Receivables	1,800,000
Inventories	2,210,000
Intangibles	3,980,000
Other current assets	60,000
Equipment	300,000
Goodwill	2,530,000
Liabilities assumed	-1,070,000
Contingent consideration	-70,000
Deferred tax liability	-50,000
	$9,690,000

Note_2_Net_Revenues_and_Operat

Note 2 - Net Revenues and Operating Income of M.C.Healthcare (Details) (M.C. Healthcare Products "MCHP" [Member], USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
M.C. Healthcare Products "MCHP" [Member]
Net revenues	$9,721,000	$11,305,000	$10,284,000
Operating income (loss)	($237,000)	$245,000	$964,000

Note_2_Proforma_Information_De

Note 2 - Pro-forma Information (Details) (M.C. Healthcare Products "MCHP" [Member], USD $)	12 Months Ended
	Sep. 29, 2012
M.C. Healthcare Products "MCHP" [Member]
Pro-forma net revenues	$78,540,000
Pro-forma net income	$5,350,000
Pro-forma net income per diluted share (in dollars per share)	$1.81

Note_3_Fair_Value_Measurement_

Note 3 - Fair Value Measurement of Assets (Details) (USD $)	Sep. 27, 2014	Sep. 28, 2013
Cash value of life insurance policies	$2,493,664	$2,318,721
Fair Value, Inputs, Level 2 [Member]
Cash value of life insurance policies	$2,493,664	$2,318,721

Note_4_Components_of_Inventori

Note 4 - Components of Inventories (Details) (USD $)	Sep. 27, 2014	Sep. 28, 2013
Raw materials	$5,476,050	$5,054,462
Work in process	517,652	698,786
Finished goods	1,899,253	1,412,702
Reserve for obsolescence	-497,000	-720,000
	$7,395,955	$6,445,950

Note_5_Summary_of_Property_and

Note 5 - Summary of Property and Equipment (Details) (USD $)	Sep. 27, 2014	Sep. 28, 2013
Land	$469,718	$469,718
Land improvements	486,698	486,698
Buildings	6,920,512	6,910,251
Machinery and equipment	8,975,185	8,233,213
Furniture and fixtures	490,479	488,346
Construction in process	17,985	201,873
Automobiles	11,313	11,461
	17,371,890	16,801,560
Less accumulated depreciation	12,483,794	11,665,025
	$4,888,096	$5,136,535

Note_6_Goodwill_Details_Textua

Note 6 - Goodwill (Details Textual) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012	Dec. 09, 2011	Oct. 01, 2011
Goodwill	4,291,843	4,487,546	$4,610,615	$4,443,302	$1,924,131
Medical [Member]
Number of Reporting Units	3	3
M.C. Healthcare Products "MCHP" [Member]
Goodwill	2,367,712			2,530,000
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	5.00%
M.C. Healthcare Products "MCHP" [Member] | Canada Revenue Agency [Member]
Percentage of Goodwill Deductible Under Canadian Tax Law	75.00%
Business Acquisition, Goodwill, Expected Tax Deductible Amount	2,000,000

Note_6_Reconciliation_of_the_C

Note 6 - Reconciliation of the Carrying Amount of Goodwill (Details) (USD $)	2 Months Ended	10 Months Ended	12 Months Ended
	Dec. 09, 2011	Sep. 29, 2012	Sep. 27, 2014	Sep. 28, 2013
Beginning balance	$1,924,131	$4,443,302	$4,487,546	$4,610,615
Asset acquisition on December 9, 2011	6,529,885
Adjustment for deferred taxes	53,149
Adjustment to increase inventories to fair market value	-160,281
Adjustment to allocate total consideration to other intangibles based on valuation	-3,971,748
Adjustment to record contingent consideration	68,166
Goodwill ,balance	4,443,302	4,610,615	4,291,843	4,487,546
Increase (decrease) in foreign currency exchange rate		$167,313	($195,703)	($123,069)

Note_7_Intangibles_Details_Tex

Note 7 - Intangibles (Details Textual) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012	Dec. 09, 2011
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived Intangible Assets, Accumulated Amortization	$2,845,250	$2,518,662
Finite-Lived Intangible Assets, Net	2,860,260	3,430,349
Amortization of Intangible Assets	394,169	479,247	422,670
Patents and Trademarks [Member]
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived Intangible Assets, Net	314,332	326,465
M.C. Healthcare Products "MCHP" [Member]
Goodwill and Intangible Assets Disclosure [Abstract]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				3,980,000
M.C. Healthcare Products "MCHP" [Member] | M C H P Acquisition Trade Names Non Compete Agreements And Customer Relationships [Member]
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived Intangible Assets, Accumulated Amortization	1,005,865	741,480
Finite-Lived Intangible Assets, Net	$2,545,928	$3,103,884

Note_7_Intangible_Assets_Detai

Note 7 - Intangible Assets (Details) (USD $)	Sep. 27, 2014	Sep. 28, 2013
Patents and trademarks	$2,153,717	$2,103,647
Trade names	404,129	437,532
Non-competition agreements	177,090	191,727
Customer relationships	2,970,574	3,216,105
	5,705,510	5,949,011
Less accumulated amortization	-2,845,250	-2,518,662
Net intangibles	$2,860,260	$3,430,349

Note_7_Estimated_Amortization_

Note 7 - Estimated Amortization Expense (Details) (USD $)	Sep. 27, 2014
2015	$350,525
2016	326,193
2017	315,359
2018	311,502
2019	$309,595

Note_8_Components_of_Other_Ass

Note 8 - Components of Other Assets (Details) (USD $)	Sep. 27, 2014	Sep. 28, 2013
Cash value of life insurance policies - Note 3	$2,493,664	$2,318,721
Other	166,468	298,216
	$2,660,132	$2,616,937

Note_9_Summary_of_Accrued_and_

Note 9 - Summary of Accrued and Sundry Liabilities (Details) (USD $)	Sep. 27, 2014	Sep. 28, 2013
Salaries and other compensation	$987,713	$1,258,897
Federal and state income taxes and sales taxes	29,472	444,473
Payroll taxes accrued and withheld	76,356	130,238
Property taxes	165,482	186,796
Medical insurance	321,635	210,551
Warranty reserve - Note 10	257,860	318,824
Customer rebates	199,600	236,000
Other	13,544	89,821
	$2,051,662	$2,875,600

Note_10_Changes_in_Product_War

Note 10 - Changes in Product Warranty Liability (Details) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013
Accrued liability at beginning of year	$318,824	$378,643
Increase in reserve	154,479	111,872
Expenses	-215,443	-171,691
Accrued liability at end of year	$257,860	$318,824

Note_11_Revolving_Credit_Facil1

Note 11 - Revolving Credit Facility (Details Textual) (USD $)	12 Months Ended			1 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012	Nov. 30, 2014	Dec. 31, 2012
Debt Disclosure [Abstract]
Long-term Line of Credit	$0	$0
Line of Credit Facility, Maximum Borrowing Capacity	10,000,000
Line of Credit Facility, Interest Rate at Period End					1.06%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Line of Credit Facility Unused Borrowing Capacity Threshold	5,000,000
Line of Credit Facility Dividend and Stock Repurchases Restrictions Percentage	50.00%
Payments of Dividends	1,683,011	4,439,382	1,358,425
Dividends Paid, Percentage of Net Income	65.00%
Interest Expense	$12,639	$15,196	$20,861
Subsequent Event [Member]
Debt Disclosure [Abstract]
Common Stock, Dividends, Per Share, Cash Paid				$1
Maximum [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Disclosure [Abstract]
Debt Instrument, Basis Spread on Variable Rate	165.00%
Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Disclosure [Abstract]
Debt Instrument, Basis Spread on Variable Rate	85.00%

Note_12_Deferred_Compensation_

Note 12 - Deferred Compensation (Details Textual) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
Deferred Compensation Arrangement with Individual, Compensation Expense	$37,000	$94,000	$59,000
Fair Value Inputs, Discount Rate	6.00%	6.00%	8.00%
Per Year [Member] | Founder [Member]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount	114,000
One-time Charge From Reduction In Disccount Rate [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense		$40,000

Note_13_Equity_Compensation_De

Note 13 - Equity Compensation (Details Textual) (USD $)	12 Months Ended			1 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012	Mar. 31, 1997	Feb. 28, 2007
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation	$26,637	$34,242	$72,264
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	26,637
The 2007 Equity Incentive Plan [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					250,000
The 2000 Restricted Stock Plan [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation	$0	$0	$2,470
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	0
The 1997 Stock Option Plan [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				200,000
Share-based Compensation Arrangement by Share-based Payment Award Award Vesting Rights Shares Vesting Per Year				1,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				20.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
The 1997 Stock Option Plan [Member] | Termination of Employment [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				90 days
Restricted Stock, Non-restricted Stock or Restricted Stock Units [Member] | The 2007 Equity Incentive Plan [Member]
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					75,000

Note_13_Summary_of_Activity_Un

Note 13 - Summary of Activity Under Two Stock Option Plans (Details) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012	Oct. 01, 2011
Balance at 10/1/11 (in shares)	190,500	190,500	190,500	190,500
Balance at 10/1/11 (in shares)	92,992	119,405	143,821	159,562
Balance at 10/1/11 (in dollars per share)	$11.53	$11.30	$10.44	$9.84
Balance at 10/1/11 (in shares)	89,592	107,605	123,621	130,962
Balance at 10/1/11 (in dollars per share)	$11.40	$10.90	$9.71	$8.74
Exercised (in shares)	-26,091	-24,416	-15,741
Expired Unexercised (in shares)	-322

Note_13_Summary_of_Stock_Optio

Note 13 - Summary of Stock Options Outstanding and Exercisable (Details) (USD $)	12 Months Ended
	Sep. 27, 2014
Exercise Price Range 2 [Member]
$ 9.18 (in dollars per share)	$14.90
$ 9.18 (in dollars per share)	$14.90
Outstanding (in shares)	36,000
Outstanding Weighted Average (in dollars per share)	$14.90
$9.18	6 years 36 days
Exercisable (in shares)	32,600
Exercisable Weighted Average (in dollars per share)	$14.90
Exercise Price Range 3 [Member]
$ 9.18 (in dollars per share)	$9.18
$ 9.18 (in dollars per share)	$14.90
Outstanding (in shares)	92,992
Outstanding Weighted Average (in dollars per share)	$11.53
$9.18	3 years 219 days
Exercisable (in shares)	89,592
Exercisable Weighted Average (in dollars per share)	$11.40
Exercise Price Range 1 [Member]
$ 9.18 (in dollars per share)	$9.18
$ 9.18 (in dollars per share)	$9.67
Outstanding (in shares)	56,992
Outstanding Weighted Average (in dollars per share)	$9.40
$9.18	2 years 36 days
Exercisable (in shares)	56,992
Exercisable Weighted Average (in dollars per share)	$9.40

Note_14_Income_Taxes_Details_T

Note 14 - Income Taxes (Details Textual) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
Income Tax Disclosure [Abstract]
Income Taxes Paid, Net	$1,904,000	$2,073,000	$1,700,000
Undistributed Earnings of Foreign Subsidiaries	$850,000

Note_14_Deferred_Tax_Liabiliti

Note 14 - Deferred Tax Liabilities and Assets (Details) (USD $)	Sep. 27, 2014	Sep. 28, 2013
Deferred tax liabilities:
Depreciation	($275,000)	($341,000)
Amortization	-52,000	-52,000
Total deferred tax liabilities	-327,000	-393,000
Deferred tax assets:
Deferred compensation	160,000	187,000
Accrued expenses	217,000	246,000
Inventory	52,000	97,000
Other	9,000	17,000
Total deferred tax assets	438,000	547,000
Net deferred tax assets	$111,000	$154,000

Note_14_Federal_State_and_Fore

Note 14 - Federal, State and Foreign Income Tax Provisions (Details) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
Current:
Federal	$1,125,000	$2,002,000	$2,037,000
State	20,000	34,000	46,000
Foreign	-150,000	16,000	234,000
	995,000	2,052,000	2,317,000
Deferred:
Federal	-11,000	159,000	-43,000
State	1,000	3,000	-4,000
Foreign	53,000	4,000	-19,000
	50,703	166,000	-66,000
Income tax expense	$1,038,000	$2,218,000	$2,251,000

Note_14_Effective_Income_Tax_R

Note 14 - Effective Income Tax Rate Reconciliation (Details) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
Computed tax at the U.S. statutory rate	$1,234,000	$2,477,000	$2,538,000
Increases (decreases):
State income taxes, net of federal tax benefit	13,000	25,000	28,000
Differences between U.S. and foreign tax rates	-27,000	-65,000	-107,000
Officer's life insurance	-57,000	-60,000	-62,000
Domestic production deduction	-116,000	-198,000	-200,000
Other, net	-9,000	39,000	54,000
Income tax expense	$1,038,000	$2,218,000	$2,251,000

Note_15_Basic_and_Diluted_Earn

Note 15 - Basic and Diluted Earnings Per Share (Details) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
Numerator for basic and diluted earnings per share:
Net income	$2,590,767	$5,067,417	$5,214,973
Denominator for basic earnings per share:
Weighted average shares (in shares)	2,948,992	2,939,684	2,892,956
Effect of dilutive securities:
Employee stock options (in shares)	44,341	54,555	53,647
Denominator for diluted earnings per share:
Adjusted weighted average shares and assumed conversions (in shares)	2,993,333	2,994,239	2,946,603
Net income per share:
Basic (in dollars per share)	$0.88	$1.72	$1.80
Diluted (in dollars per share)	$0.87	$1.69	$1.77

Note_16_Employee_Benefits_and_1

Note 16 - Employee Benefits and Incentive Plans (Details Textual) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
Pension and Other Postretirement Benefit Expense [Abstract]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$184,000	$202,000	$190,000

Note_17_RelatedParty_Transacti1

Note 17 - Related-Party Transactions (Details Textual) (USD $)	12 Months Ended	1 Months Ended
	Sep. 28, 2013	Aug. 31, 2013
Related Party Transactions [Abstract]
Stock Repurchased and Retired During Period, Value	$450,000
Former Owner of M.C. Healthcare [Member] | Share Repurchase Program [Member]
Related Party Transactions [Abstract]
Stock Repurchased and Retired During Period, Shares		25,000
Treasury Stock Acquired, Average Cost Per Share		$18
Stock Repurchased and Retired During Period, Value		$450,000

Note_18_Major_Customers_Detail

Note 18 - Major Customers (Details Textual) (Sales Revenue, Net [Member], Customer Concentration Risk [Member])	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
Distributor 3[Member]
Risks and Uncertainties [Abstract]
Concentration Risk, Percentage	16.00%	32.00%	34.00%
Distributors for the United States and Canada [Member]
Risks and Uncertainties [Abstract]
Concentration Risk, Percentage	17.00%	13.00%	11.00%

Note_19_Operations_and_Industr2

Note 19 - Operations and Industry Segments and Geographic Areas (Details Textual) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
Segment Reporting [Abstract]
Number of Reportable Segments	2
Canada [Member]
Segment Reporting [Abstract]
Net Assets	10,000,000	11,000,000
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Another Customer [Member] | Medical [Member]
Segment Reporting [Abstract]
Concentration Risk, Percentage	11.00%	9.00%	9.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Customer One [Member] | Custom Products [Member]
Segment Reporting [Abstract]
Concentration Risk, Percentage	66.00%	88.00%	88.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Two Combined Customers [Member] | Medical [Member]
Segment Reporting [Abstract]
Concentration Risk, Percentage	22.00%	21.00%	17.00%

Note_19_Information_on_Industr

Note 19 - Information on Industry Segments (Details) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
Net sales	$55,857,375	$73,833,549	$76,146,423
Operating profit	4,224,602	7,955,379	8,147,375
Other income (expense)	18,187	-9,022	-44,092
Income before income taxes	3,628,767	7,285,417	7,465,973
Identifiable assets	35,846,834	36,376,628	37,647,766
Property and Equipment, net	4,888,096	5,136,535	5,390,675
Goodwill	4,291,843	4,487,546	4,610,615
Intangibles, net	2,860,260	3,430,349	3,990,887
Canada [Member]
Net sales	5,922,543	7,506,498	7,920,424
Property and Equipment, net	706,735	620,833	347,415
Goodwill	2,367,712	2,563,415	2,686,484
Intangibles, net	2,556,804	3,103,884	3,676,962
Other Areas [Member]
Net sales	130,173	104,184	244,067
United States [Member]
Net sales	49,804,659	66,222,867	67,981,932
Property and Equipment, net	4,181,361	4,515,702	5,043,260
Goodwill	1,924,131	1,924,131	1,924,131
Intangibles, net	303,456	326,465	313,925
Corporate Segment [Member]
Corporate expense	-614,022	-660,940	-637,310
Identifiable assets	9,633,841	8,095,020	4,802,460
Custom products	409	409	303
Medical	670,845	557,863	684,327
Custom Products [Member]
Net sales	13,522,479	26,301,873	29,694,415
Operating profit	257,997	2,509,105	2,797,465
Identifiable assets	3,991,467	5,769,403	9,030,782
Custom products	218,234	296,754	336,114
Medical	75,843	80,935	206,669
Medical [Member]
Net sales	42,334,896	47,531,676	46,452,008
Operating profit	3,966,605	5,446,274	5,349,910
Identifiable assets	22,221,526	22,512,205	23,814,524
Medical	$595,002	$476,928	$477,658

Note_20_Operating_Leases_Detai

Note 20 - Operating Leases (Details Textual) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
Leases, Operating [Abstract]
Operating Leases, Rent Expense	$375,000	$424,000	$414,000
Showroom Facility in Beamsville, Ontario [Member]
Leases, Operating [Abstract]
Area of Real Estate Property	50,000
Operating Leases, Rent Expense, Minimum Rentals	265,000
Lessee Leasing Arrangements, Operating Leases, Term of Contract	5 years
Lessor Leasing Arrangements, Operating Leases, Renewal Term	5 years
Utah Facility [Member]
Leases, Operating [Abstract]
Area of Real Estate Property	15,000
Operating Leases, Rent Expense, Minimum Rentals	$7,500

Note_21_Commitments_and_Contin1

Note 21 - Commitments and Contingencies (Details Textual) (USD $)	12 Months Ended
	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
Commitments and Contingencies Disclosure [Abstract]
Purchase Obligation, Due in Next Twelve Months	$700,000
Unrecorded Unconditional Purchase Obligation, Purchases	$898,000	$1,047,000	$898,000

Note_22_Quarterly_Financial_Da2

Note 22 - Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 29, 2013	Mar. 30, 2013	Dec. 29, 2012	Sep. 27, 2014	Sep. 28, 2013	Sep. 29, 2012
Net sales	$13,045,000	$13,251,000	$14,709,000	$14,853,000	$16,929,000	$18,621,000	$16,623,000	$21,661,000	$55,857,375	$73,833,549	$76,146,423
Gross profit	4,405,000	4,343,000	5,253,000	4,788,000	5,419,000	6,225,000	5,777,000	6,143,000	18,789,638	23,563,892	23,522,130
Operating income	702,000	563,000	1,341,000	1,005,000	1,590,000	1,814,000	1,813,000	2,077,000	3,610,580	7,294,439	7,510,065
Net income	$656,000	$378,000	$891,000	$666,000	$1,247,000	$1,223,000	$1,234,000	$1,364,000	$2,590,767	$5,067,417	$5,214,973
Basic (in dollars per share)	$0.22	$0.13	$0.30	$0.23	$0.42	$0.41	$0.42	$0.47	$0.88	$1.72	$1.80
Diluted (in dollars per share)	$0.22	$0.13	$0.30	$0.22	$0.42	$0.41	$0.41	$0.46	$0.87	$1.69	$1.77

Note_23_Schedule_of_Valuation_

Note 23 - Schedule of Valuation and Qualifying Accounts (Details) (USD $)	12 Months Ended
	Sep. 27, 2014		Sep. 28, 2013		Sep. 29, 2012
Allowance for Doubtful Accounts [Member]
Balance at beginning of period	$263,000		$233,000		$150,000
Charged to costs and expenses	128,925		91,623		32,000
Deductions-describe	89,925	[1]	61,623	[1]	9,000	[1]
Balance at end of period	302,000		263,000		233,000
Adjustments					60,000	[2]
Inventory Valuation Reserve [Member]
Balance at beginning of period	720,000		595,000		245,000
Charged to costs and expenses	95,303		145,000		127,000
Deductions-describe	318,303	[3]	20,000	[3]	7,000	[3]
Balance at end of period	497,000		720,000		595,000
Adjustments					$230,000	[2]
[1]	Uncollectible accounts written off
[2]	Adjustments related to acquisitions and translation
[3]	Inventory disposed of